Saturday, June 25, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

The safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in adults previously vaccinated with BBIBP-CorV

by Medical Finance
in Coronavirus
Study: Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial. Image Credit: Rawpixel.com/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the medRxiv* preprint server, researchers assessed the safety profile and immunogenicity of a heterologous NVSI-06-08 boost against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in individuals doubly vaccinated with the inactivated vaccine BBIBP-CorV.

Study: Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial. Image Credit: Rawpixel.com/Shutterstock
Study: Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial. Image Credit: Rawpixel.com/Shutterstock

Background

The decline of coronavirus disease 2019 (COVID-19) vaccine-induced immune responses against SARS-CoV-2 strains warrants the need for booster doses to restore and enhance the protective serological immunity. NVSI-06-08 vaccine comprises a trimeric antigen with mutation-integrated receptor-binding domain (RBDs) of the spike (S) protein of the prototype, Kappa, and Beta strains. Thus, NVSI-06-08 is a hybrid vaccine with efficacy against the three SARS-CoV-2 strains.

About the study

In the present study, researchers conducted a randomized, controlled, phase 2 clinical trial to evaluate the immunogenic potency and safety of the heterologous NVSI-06-08 vaccine booster in inactivated BBIBP-CorV vaccine recipients.  

Over 1800 participants, aged over 18 years, were recruited for the study. They were divided into three groups of 600 individuals, each with differing prime-boosting time intervals: four-six months, seven-nine months, and greater than nine months. A total of 200 blood samples from heterologous boosted participants (n=99) and homologous boosted controls (n=101) were obtained 15 days post-vaccine boosting. The primary outcomes were immunogenicity and safety, whereas the exploratory outcome was cross-protective immunity against SARS-CoV-2.

The neutralizing antibody and immunoglobulin G (IgG) titers were quantified using the live-virus neutralization assay and the chemiluminescence enzyme immunoassay, respectively. Additionally, the immune response against SARS-CoV-2 Beta, Delta, and Alpha strains was determined.

All 1800 booster-vaccinated subjects comprised the Safety Set (SS) for safety assessment. Out of 1800 participants, 1678 without protocol deviations during follow-up comprised the Perprotocol set (PPS) to evaluate immunogenicity. Additionally, the geometric mean titers (GMT) and geometric mean concentrations (GMC) post homologous and heterologous boost were calculated 15- and 30-days post boosting.

Results

About 16% and 13% heterologous and homologous boosted subjects, respectively, reported a minimum of one solicited grade 2 or 1 adverse event within a week of boosting. The most common were pain at the site of injection. Systemic reactions reported were also graded 2 or 1 and comprised muscle pain, headache, fever, and fatigue. Grade 3 generalized side effects, including muscle pain and fever, were observed in only 0.2%, 0.5%, and 0.2% of participants boosted by homologous and heterologous vaccines, respectively. The unsolicited adverse reactions observed were cough, myalgia, and fever, most being grade 2 or 1. No one reported grade 4 adverse effects. This indicates that the NVSI-06-08 heterologous boost was well tolerated and had a safety profile similar to that of the homologous boost.

Significantly elevated IgG titers were detected against the viral prototype strain with both boosters. About 15 days post homologous boost, GMTs improved by 2.9-fold, 10.3-fold, and 21-fold in the four-six-months, seven-nine-months, and greater than nine months groups, respectively. On the other hand, those induced by heterologous boost increased by 40-fold, 94-fold, and 247-fold, respectively.

Correspondingly, the four-fold rates of the homologous boost were 23%, 75%, and 94% in four-six-month, seven-nine-month, and greater than nine-months, respectively. In contrast, those heterologous boosted were 94%, 98%, and 99.7%, respectively. These GMTs and four-fold rates increased further within a month of a booster vaccination. Notably, the heterologous boost antibody titers were substantially high in the seven-nine months and exceeding nine months groups with GMTs as high as 7719 against the wild-type strain in the seven-nine-months group.

Post 15 days of boosting, the anti-RBD GMCs improved by 49 to 63-fold post heterologous boost and two to three-fold by homologous boosting. Likewise, the heterologous boost four-fold increase was substantially higher than the homologous boost in all groups (91%-96% vs. 21%-32%).

A month post boosting, the heterologous boost IgG GMCs increased by 44-fold, 37-fold, and 41-fold in four-six-months, seven-nine-months, and greater than nine months groups, respectively. Correspondingly, the four-fold increase by heterologous boost was 95%, 92%, and 88%, respectively. Both the GMCs and four-fold increases were much higher after the heterologous boost.

The homologous boost GMTs was 45 for the Omicron strains, whereas the heterologous boost GMT against Omicron was maintained at a much higher level of 368. This indicates that the heterologous boost was more effective against the immune-evasive Omicron variant. Additionally, the heterologous boost GMTs were 11-fold, 15-fold, and 10-fold higher than homologous boosting against Alpha, Beta, and Delta strains, respectively.

The heterologous NVSI-06-08 booster was safe and immunogenic when administered six months post-primary vaccination with BBIBP-CorV and offers improved cross-protective immunity.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Immune and pathophysiologic profiling of antenatal COVID-19 in the GIFT cohort: A Singaporean case-control study. Image Credit: wong sze yuen/Shutterstock

Durability and neutralization capacity of SARS-CoV-2 specific antibodies in the breastmilk of convalescent COVID-19 mothers

by Medical Finance
June 25, 2022
0

In a recent study posted to the medRxiv* preprint server, the researchers assessed immunological and pathophysiological aspects of antenatal coronavirus...

Study: Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome. Image Credit: Ralf Liebhold/Shutterstock

The impact of leronlimab on CCR5 surface cell levels during long COVID

by Medical Finance
June 25, 2022
0

In a recent study published in the Clinical Infectious Diseases journal, researchers assessed the impact of long coronavirus disease 2019...

Oranges infested with Amarelinho or CVC, Citrus Variegated Chlorosis, which is a disease caused by the bacterium Xylella fastidiosa

The role of invasive alien species as a reservoir of pathogens

by Medical Finance
June 25, 2022
0

Many studies have indicated that wild animals can harbor dangerous zoonoses. In addition, European wild plants and many house and...

Study: A COVID-19 Vaccine for Dogs Prevents Reverse Zoonosis. Image Credit: LightField Studios/Shutterstock

Canine COVID-19 vaccine could prevent reverse transmission of SARS-CoV-2

by Medical Finance
June 25, 2022
0

Even as the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing...

Study: Repurposing Halicin as a Potent Covalent Inhibitor for the SARS-CoV-2 Main Protease. Image Credit: Kateryna Kon/Shutterstock

The potency of halicin against the main protease of SARS-CoV-2

by Medical Finance
June 25, 2022
0

The coronavirus disease 2019 (COVID-19) caused a global public health disaster, costing millions of human lives and stressing national healthcare...

Study: Association of Short-term Air Pollution Exposure With SARS-CoV-2 Infection Among Young Adults in Sweden. Image Credit: Elwyn / Shutterstock

Unhealthy air increases the chances of catching COVID-19

by Medical Finance
June 25, 2022
0

Does exposure to air pollution increase the risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and...

Next Post
Study: Polymorphism in IFNAR contributes to glucocorticoid response and outcome in ARDS and COVID-19. Image Credit: rumruay/Shutterstock

Study suggests single nucleotide polymorphism in interferon receptor impacts COVID-19 outcomes

Study: The impact of COVID-19 non-pharmaceutical interventions on future respiratory syncytial virus transmission in South Africa. Image Credit: DisobeyArt/Shutterstock

Impact of COVID-19 measures on the future transmission of respiratory syncytial virus

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Genetics 620x480
    Study determines how genetics and environmental conditions interact during plant development
  • Study: Molecular dynamics and docking studies on potentially active natural phytochemicals for targeting SARS-CoV-2 Main Protease. Image Credit: Kateryna Kon/Shutterstock
    Study shows potential inhibition of SARS-CoV-2 main protease by natural phytochemicals
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply